ASND
Ascendis Pharma A/SNASDAQHealthcare$229.25+0.44%ClosedMarket Cap: $14.07B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-75.04
P/S
17.01
EV/EBITDA
-154.53
DCF Value
$-4,838.78
FCF Yield
0.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.3%
Operating Margin
-19.0%
Net Margin
-31.7%
ROE
127.5%
ROA
-17.5%
ROIC
-19.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $245.2M | 88.9% | $9.8M | $-33.2M | $-0.54 | — |
| FY 2025 | $691.7M | 85.1% | $-130.9M | $-219.0M | $-3.62 | — |
| Q3 2025 | $213.6M | 89.5% | $11.0M | $-61.0M | $-1.00 | — |
| Q2 2025 | $158.0M | 80.1% | $-53.0M | $-38.9M | $-0.82 | — |
| Q1 2025 | $101.0M | 82.6% | $-104.2M | $-94.6M | $-1.58 | — |
| Q4 2024 | $173.9M | 91.9% | $383.0K | $-38.5M | $-0.64 | — |
| FY 2024 | $363.6M | 87.8% | $-278.8M | $-378.1M | $-6.53 | — |
| Q3 2024 | $57.8M | 80.6% | $-96.7M | $-99.2M | $-1.69 | — |
| Q2 2024 | $36.0M | 68.2% | $-133.3M | $-109.4M | $-1.91 | — |
| Q1 2024 | $95.9M | 92.1% | $-49.1M | $-131.0M | $-2.30 | — |
| Q4 2023 | $137.7M | 85.9% | $-36.6M | $-86.9M | $-1.53 | — |
| FY 2023 | $266.7M | 83.4% | $-455.5M | $-481.4M | $-8.55 | — |